{"id": "1358860652354433024", "creation": 1612812600.0, "user_id": "18026170", "social_network": "twitter", "nsfw": false, "request": ["b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc"], "metrics": {"b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc": {"retweet_count": 0, "reply_count": 0, "like_count": 1, "quote_count": 0}}, "text": ".@covaxxvaccine sees good response &amp; safety in interim Ph1 #ClinicalTrials of UB-612 #COVID19 #vaccine\n\nIn adults, 2 doses induced #neutralizing #antibodies in 100% of subjects; comparable to #convalescent sera\n\nhttps://t.co/WpPJno1U7w\n#SARSCoV2 #InfectiousDiseases @russopartners https://t.co/yBSVIBaYyC", "first_save": 1634559108.199414, "hashtags": ["#CLINICALTRIALS", "#COVID19", "#VACCINE", "#NEUTRALIZING", "#ANTIBODIES", "#CONVALESCENT", "#SARSCOV2", "#INFECTIOUSDISEASES"]}